Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
E. Wittermans (Nieuwegein, Netherlands), S. Vestjens (Nieuwegein, Netherlands), S. Spoorenberg (Nieuwegein, Netherlands), W. Blok (Amsterdam, Netherlands), J. Grutters (Nieuwegein, Netherlands), R. Janssen (Nijmegen, Netherlands), G. Rijkers (Middelburg, Netherlands), F. Smeenk (Eindhoven, Netherlands), P. Voorn (Nieuwegein, Netherlands), E. Van De Garde (Nieuwegein, Netherlands), W. Bos (Nieuwegein, Netherlands)
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Session: ALERT: Infection in adults and children
Session type: Clinical trials session
Number: 4132
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Wittermans (Nieuwegein, Netherlands), S. Vestjens (Nieuwegein, Netherlands), S. Spoorenberg (Nieuwegein, Netherlands), W. Blok (Amsterdam, Netherlands), J. Grutters (Nieuwegein, Netherlands), R. Janssen (Nijmegen, Netherlands), G. Rijkers (Middelburg, Netherlands), F. Smeenk (Eindhoven, Netherlands), P. Voorn (Nieuwegein, Netherlands), E. Van De Garde (Nieuwegein, Netherlands), W. Bos (Nieuwegein, Netherlands). Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial. 4132
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020 Year: 2021
Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019
Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015
LATE-BREAKING ABSTRACT: Intravenous infusion of Chinese medicine xuebijing significantly improved clinical outcome in severe pneumonia patients in a multiple center randomized controlled clinical trials Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Procalcitonin-guided antibiotic therapy in acute exacerbations of COPD (AECOPD): a randomised trial - The ProCOLD Study Source: Eur Respir J 2005; 26: Suppl. 49, 464s Year: 2005
Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? Source: Eur Respir J 2013; 41: 5-6 Year: 2013
Efficacy of azithromycin in severe asthma from the AMAZES randomised trial Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019 Year: 2019
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Randomized, controlled trial of efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020 Year: 2020
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013
Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients. Source: International Congress 2019 – Comorbidities galore in respiratory patients Year: 2019